ArticleCancer2022

Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.

Francesca Palandri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.